key: cord-0064818-bcyttoy0 authors: Goud, B. K. Manjunatha; Sharma, Dharmendra; Varanasi, Sreya title: A review on COVID-19 for medical students date: 2021-05-29 journal: Indian J Med Sci DOI: 10.25259/ijms_47_2020 sha: 0e97e7a26e6cce715af4118f265b28c2d3c6cf2c doc_id: 64818 cord_uid: bcyttoy0 It has not been very long since the SARS-CoV 2002 and MERS-CoV 2012 epidemics. Yet again, nature has introduced SARS-CoV-2, also known as COVID-19, a highly virulent strain of the coronavirus that has its origin in the city of Wuhan, Hubei Province, China. Primarily, a zoonotic infection, the virus probably found its way to humans through infected wild bats sold in the Wuhan local market. What makes the virus virulent, is its ability to infect multiple people at once through single index case. This has led to inability to contain the virus with ease posing a significant threat to national and international health-care resources and economies. The objective of this review is to highlight the key features of the novel CoV-19 infection as per existing data for better understanding of the disease. nCoV-19 infected the index cases. Among humans, the virus is transmitted through nasopharyngeal droplets and fomites. [5] [6] [7] On December 12, 2019, a case of pneumonia not caused by influenza or other known CoV was first reported in Wuhan. By December 31, 2019, 27 similar cases were diagnosed in the same province. [8, 9] All cases reported a history of animal contact in the above-mentioned market. On January 7, 2020, the Government of China announced that nCoV-19 was isolated from all the above cases. [10, 11] Like other coronavirus outbreaks, COVID-19 seems to exhibit high incidence in the spring season across the globe. Being the season of celebrations and gatherings, high population densities in smaller areas assist in the easy transmission of the virus among humans. Compounded by the increase in international travel, the above-mentioned factors pose significant difficulties for countries to contain the spread of the virus. [12] GENETICS According to research, SARS-CoV-2 is like SARS-CoV in 70% of its genome and to MERS-CoV in 50% of its genome. It has approximately 89% similarity with two batderived SARS-like CoVs. [13] [14] [15] Metagenomic next-generation sequencing revealed the entire 29,881 base pair genome of the virus with 6-11 open reading frames (ORFs). [16] Evolutionary analysis based on ORF1a/1b, S, and N genes suggests that SARS-CoV-2 was independently introduced from animals to humans. [17, 18] Two-thirds of the viral RNA, located in the first ORF (ORF1a/b), translates to two polyproteins, PP1a and PP1ab and encodes 16 non-structural proteins (NSP). One-third of the viral genome encodes four essential structural proteins and several accessory proteins that interfere with the host innate immune response: [19] 1. Spike (S) glycoprotein 2. Small envelope (E) protein 3. Matrix (M) protein 4. Nucleocapsid (N) protein SARS-CoV-2 possesses the S-glycoprotein gene and receptor-binding domain (RBD) which confer the ability to be transmitted between two humans by direct contact. When comparing SARS-CoV-2 with other known CoVs, no difference was found in the amino acid sequences of NSP7, NSP13, envelope, matrix, or accessory proteins p6 and 8b. A few differences were found in the NSP2, NSP3, spike protein, and underpinning subdomain (RBD). [20] Mutations in NSP2 and NSP3 play a role in the infectious potential and differentiation mechanism of the virus. [21] Zhang et al. [22] found that as the virus spread across different provinces in China, its genotype exhibited several mutations. [23] PATHOGENESIS The viral surface S glycoprotein has 2 subunits: [24] • S1 -responsible for defining the host range, plays a role in cellular tropism. The most common clinical presentation is fever, headache, sore throat, productive wet cough, myalgia, diarrhea, and dyspnea. [33] [34] [35] The spectrum of clinical cases includes asymptomatic carriers and mild respiratory infection that recover within a week, severe progressive respiratory distress and death. [34, 36] In severe respiratory distress, respiratory system examination reveals reduced tactile fremitus, dullness to percussion, and reduced air entry associated with rales. Majority of the case fatalities have been reported among the middle-aged and elderly population associated with multiple comorbidities such as diabetes mellitus, hypertension, coronary artery disease, liver cirrhosis, and cancer. [37] INVESTIGATIONS Investigations can be divided into two classes: 1. Tests to confirm the diagnosis of COVID 19 -a positive RT-PCR test. 2. Tests to monitor and assess the severity of the disease and its progression -performed in critically ill-hospitalized patients. A patient is declared as recovered from the infection if two samples taken on different days give a negative RT-PCR result. Routine blood tests include the following: 1. Complete blood count: It shows decrease in lymphocytes and white blood cells with specific reduction in CD4 and CD8 T-cells. Chest X-rays are the initial imaging modality followed by CT thorax without contrast. Clues to the diagnosis of COVID-19 on a chest X-ray are as follows: • Bilateral lung infiltrates along the subpleural plane and bronchial vascular bundles, singular or multiple patchy, nodular, and honeycomb-or cord-like infiltrates, particularly involving the middle and lower lobes of the lung. • Typical bilateral subsegmental ground-glass appearance • Interlobular thickening • Consolidation and thickening of bronchial walls Atypical findings on imaging include: • Pleural effusion • Enlargement of mediastinal lymph nodes RTC continuously replicates and synthesizes sub genomic RNAs which encode accessory and structural proteins [31] [32] Newly formed genomic RNA , nucleocapsid proteins and envelop glycoproteins assemble to form daughter viral particles. Newly formed virion vesicles are released from the host cells via exocytosis. • Single or multiple solid nodules or consolidated nodules in the center of lobule surrounded by ground-glass opacities. CT STAGING [38] Stages Type of patients Radiological features General guidelines include: • Supportive therapy: Rest and symptomatic treatment with antipyretics, nutritional supplements, and proton-pump inhibitors/ranitidine to prevent stress ulcers. Contraindicated in a history of recent surgery, bleeding disorders, suspected hemorrhage, active ulcers, and allergy to heparin. Antivirals: • These drugs are not specific for treatment of SARS-CoV-2 but may help to improve the patient's overall condition. • Example: Lopinavir, ritonavir, and interferon-alpha • Remdesivir is a 1-cyano-substituted adenosine nucleotide analog prodrug with broad-spectrum antiviral activity against several RNA viruses. The first reported case of COVID-19 in the USA was successfully treated by remdesivir. [39] Antimalarials: • Chloroquine [40] shows great potential in the treatment of COVID-19 according to in vitro studies through the following mechanisms: • Inhibiting pH-dependent steps of viral replication [41] • Immunomodulatory effects through suppression of TNF and IL-6 production [42] • Impaired glycosylation of host cell receptors for SARS-CoV-2 [43] [44] [45] [46] • Antibiotics to prevent secondary bacterial infections • Corticosteroids in rapid progressive disease: Its impact on length of hospital stay is yet to be determined. The following complications have been reported to date: [33, 47] • ARDS • Arrhythmia • Shock -circulatory and septic • Acute kidney injury • Liver dysfunction According to the WHO, by practicing the following five steps, we can successfully prevent the spread of nCoV-19 to others and avoid being infected by it ourselves: [47] • Frequent handwashing with soap and water or an alcohol-based hand rub for at least 20 s. • Social distancing by at least 1 m or 3 ft with people who are unwell. • Covering the nose and mouth with a disposable tissue or a flexed elbow when coughing or sneezing. Dispose the used tissue immediately. Avoid touching your face repeatedly, especially if your hands are dirty. • Self-isolation (#StayHome) -especially if you feel unwell. • Seek medical attention immediately if the following symptoms develop: Fever, cough, and difficulty breathing. At a global level, countries across the world have imposed nationwide lockdowns and public health protocols to contain the spread of COVID-19 and protect the health of their residents. Some of the measures include: • Temporary closure of international travel • Surveillance and screening of suspected individuals • Isolation of infected individuals with quarantine of their close contacts • Nationwide sterilization drives. From the time, SARS-CoV-2 made its appearance among humankind, several researchers and health-care professionals have been risking their lives to understand the properties of the virus and aid in the recovery of infected individuals while preventing its spread among communities. By implementing lessons learned from the previous coronavirus epidemics, we can design an effective vaccine and antiviral drug that will help combat the virus. A lot more knowledge is yet to be obtained regarding the virus and the disease which will better enable us to manage patients and reduce mortality rates. Patient's consent not required as there are no patients in this study. Nil. There are no conflicts of interest. Coronavirus genomics and bioinformatics analysis Genomic characterization of severe acute respiratory syndrome-related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA polymerase gene sequences SARS and other coronaviruses as causes of pneumonia Severe Acute Respiratory Syndrome-Related Coronavirus: The Species and its Viruses-a Statement of the Coronavirus Study Group. BioRxiv; 2020 The first two cases of 2019-nCoV in Italy: Where they come from Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event Estimating the Potential Total Number of Novel Coronavirus Cases in Wuhan City, China; 2020 World Health Organization. 2019-nCoV Situation Report-22 European Centre for Disease Prevention and Control Data: Geographical Distribution of 2019-nCov Cases Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding From SARS-CoV to Wuhan 2019-nCoV Outbreak: Similarity of Early Epidemic and Prediction of Future Trends A novel coronavirus from patients with pneumonia in China An emerging coronavirus causing pneumonia outbreak in Wuhan, China: Calling for developing therapeutic and prophylactic strategies From SARS to MERS, thrusting coronaviruses into the spotlight RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak A pneumonia outbreak associated with a new coronavirus of probable bat origin Origin and evolution of pathogenic coronaviruses Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China COVID-2019: The role of the nsp2 and nsp3 in its pathogenesis Origin and evolution of the 2019 novel coronavirus Poultry farms as a source of avian influenza a (H7N9) virus reassortment and human infection Current advancements and potential strategies in the development of MERS-CoV vaccines Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia Structural insights into coronavirus entry Host factors in coronavirus replication Coronavirus transcription: A perspective Identification of novel subgenomic RNAs and noncanonical transcription initiation signals of severe acute respiratory syndrome coronavirus The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal Clinical characteristics of coronavirus disease 2019 in China Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Beijing union medical college hospital on "pneumonia of novel coronavirus infection" diagnosis and treatment proposal (V2.0) A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia First case of 2019 novel coronavirus in the United States Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity Effects of chloroquine on viral infections: An old drug against today's diseases? Quinoline-based antimalarial drugs: A novel class of autophagy inhibitors Chloroquine is a potent inhibitor of SARS coronavirus infection and spread Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset Ribavirin and interferon alfa-2a for severe middle east respiratory syndrome coronavirus infection: A retrospective cohort study Clinical analysis of 190 cases of outbreak with atypical pneumonia in Guangzhou in spring Use of glucocorticoid in treatment of severe acute respiratory syndrome cases Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China World Health Organization